Dr. Udit Verma on Regorafenib in Patients With mCRC

Udit Verma, MD
Published: Wednesday, Apr 13, 2016



Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

In the phase IIIB CONSIGN study, 2872 patients with mCRC who failed standard therapy were treated with regorafenib, which demonstrated a median progression-free survival of 2.7 months. This retrospective subgroup analysis sought to confirm previous findings as well as the safety profile of regorafenib. This study’s primary endpoint was safety, Verma adds.

The most common grade 3 adverse events were hand-foot skin reaction (16%), hypertension (15%), fatigue, and diarrhea. These findings were similar as to what was reported in the phase III CORRECT trial, Verma explains.



Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

In the phase IIIB CONSIGN study, 2872 patients with mCRC who failed standard therapy were treated with regorafenib, which demonstrated a median progression-free survival of 2.7 months. This retrospective subgroup analysis sought to confirm previous findings as well as the safety profile of regorafenib. This study’s primary endpoint was safety, Verma adds.

The most common grade 3 adverse events were hand-foot skin reaction (16%), hypertension (15%), fatigue, and diarrhea. These findings were similar as to what was reported in the phase III CORRECT trial, Verma explains.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x